Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 178, 104746
Abstract
No abstract availableKeywords
Funding Information
- Ministerie van Economische Zaken en Klimaat
- Ministerie van Economische Zaken (LSHM16056)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- International Studies Association
- Maag Lever Darm Stichting
This publication has 38 references indexed in Scilit:
- Cross-presentation by dendritic cellsNature Reviews Immunology, 2012
- Monocyte-Derived Dendritic Cells Exhibit Increased Levels of Lysosomal Proteolysis as Compared to Other Human Dendritic Cell PopulationsPLOS ONE, 2010
- Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cellsJournal of Experimental Medicine, 2010
- Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensJournal of Experimental Medicine, 2010
- Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels?Gut, 2009
- Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8+ and CD4+ T CellsJournal of Biological Chemistry, 2009
- Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cellsMolecular Immunology, 2009
- Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell RepertoireJournal of Virology, 2008
- Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentationEuropean Journal of Immunology, 2008
- Dendritic cells: Understanding immunogenicityEuropean Journal of Immunology, 2007